Dolutegravir is the first integrase inhibitor available as a dispersible tablet for oral suspension for children weighing at least 3kg and from four weeks of age. The FDA approval is testament to the ...

The formulation and an expanded indication for Tivicay tablets are currently under review in Europe The US Food and Drug Administration has approved the first-ever dispersible tablet formulation of ...

The US Food and Drug Administration (FDA) has approved the first dispersible tablet formulation of dolutegravir (Tivicay PD, ViiV Healthcare) to treat HIV-1 infection in children at least 4 weeks old ...

SAN DIEGO — A film-coated tablet formulation of deferasirox demonstrated higher patient satisfaction than the dispersible tablet formulation among patients with transfusion-dependent thalassemia and ...

ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe - Dolutegravir is the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved dolutegravir tablets and dolutegravir tablets for oral suspension to treat HIV infection, ...

First dispersible tablet formulation of Tivicay now available for children in the EU ViiV Healthcare has bagged a marketing authorisation for a dispersible tablet formulation of its HIV-1 treatment ...

Approved by Swissmedic, sweet-tasting Coartem® Dispersible is an easy-to-administer medicine that promotes effective treatment for children with malaria Recent study published in The Lancet shows ...

A new sweetened, cherry-flavoured dispersible antimalarial tablet is as effective as the crushed, currently used variety, which needs to be crushed before administration to small children, resulting ...

ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV Dolutegravir is the first ...